514 results on '"Mongkolsapaya, Juthathip"'
Search Results
2. The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86
3. Concerted deletions eliminate a neutralizing supersite in SARS-CoV-2 BA.2.87.1 spike
4. Immunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: A prospective observational study in Vietnam
5. The alteration of NK cells phenotypes related to the functions and dengue disease outcomes
6. A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity
7. Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
8. Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history
9. Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination
10. Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses
11. Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region
12. A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75
13. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination
14. KIR copy number variations in dengue-infected patients from northeastern Thailand
15. Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibition.
16. The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies
17. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study
18. An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease
19. CryoEM structures of the multimeric secreted NS1, a major factor for dengue hemorrhagic fever
20. Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
21. Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum
22. Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays
23. Guillain-Barré Syndrome Following Zika Virus Infection Is Associated With a Diverse Spectrum of Peripheral Nerve Reactive Antibodies
24. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
25. Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey
26. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
27. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient
28. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus
29. A haemagglutination test for rapid detection of antibodies to SARS-CoV-2
30. Flavivirus maturation leads to the formation of an occupied lipid pocket in the surface glycoproteins
31. AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults.
32. Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection
33. Immunogenicity and durability against micron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
34. Heterologous prime-boost immunization induces protection against dengue virus infection in cynomolgus macaques
35. A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection
36. Preligand Assembly Domain-Mediated Ligand-Independent Association between TRAIL Receptor 4 (TR4) and TR2 Regulates TRAIL-Induced Apoptosis
37. Evolution of neurovirulent Zika virus
38. Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera
39. Cooperativity and induced oligomerisation control the interaction of SARS- CoV-2 with its cellular receptor and patient-derived antibodies
40. Analysis of emergent bivalent antibody binding identifies the molecular reach as a critical determinant of SARS-CoV-2 neutralisation potency
41. Blockade-of-Binding Activities toward Envelope-Associated, Type-Specific Epitopes as a Correlative Marker for Dengue Virus-Neutralizing Antibody
42. Antibodies targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during pregnancy
43. Autoantibody-dependent amplification of inflammation in SLE
44. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in T Cell Development: Sensitivity of Human Thymocytes
45. Identification and characterisation of new apoptosis proteins and their application in pathogenesis
46. Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus
47. The immune response against flaviviruses
48. Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
49. Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses
50. Rapid escape of new SARS-CoV-2 Omicron variants from BA.2 directed antibody responses
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.